Angiodynamics (ANGO) Change in Accured Expenses (2016 - 2026)
Angiodynamics' Change in Accured Expenses history spans 17 years, with the latest figure at -$6.0 million for Q1 2026.
- For Q1 2026, Change in Accured Expenses rose 45.17% year-over-year to -$6.0 million; the TTM value through Feb 2026 reached -$10.9 million, down 42.43%, while the annual FY2025 figure was -$15.9 million, 157.67% down from the prior year.
- Change in Accured Expenses reached -$6.0 million in Q1 2026 per ANGO's latest filing, down from $3.2 million in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $17.7 million in Q1 2024 to a low of -$16.5 million in Q3 2023.
- Average Change in Accured Expenses over 5 years is $511176.5, with a median of $2.6 million recorded in 2025.
- Peak YoY movement for Change in Accured Expenses: tumbled 446.88% in 2022, then skyrocketed 515.14% in 2024.
- A 5-year view of Change in Accured Expenses shows it stood at $6.1 million in 2022, then skyrocketed by 153.34% to $15.6 million in 2023, then plummeted by 51.97% to $7.5 million in 2024, then crashed by 57.48% to $3.2 million in 2025, then plummeted by 289.06% to -$6.0 million in 2026.
- Per Business Quant, the three most recent readings for ANGO's Change in Accured Expenses are -$6.0 million (Q1 2026), $3.2 million (Q4 2025), and -$10.7 million (Q3 2025).